[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507974":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":37,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":10,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Renmin Hospital of Wuhan University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Neoadjuvant chemotherapy combi",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Yong Shun Chen","CONTACT","86+153 2712 2084","yongshun2007@163.com",[18],{"facility":19,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Renmin hosptial of Wuhan University","RECRUITING","Wuhan","Hubei","430060","China","CN",{"type":27,"coordinates":28},"Point",[29,30],114.26667,30.58333,{"lat":30,"lon":29},[33],{"name":34,"role":14,"phone":35,"phoneExt":10,"email":36},"Li Wei Chen","86+15671578311","wdrmiit@163.com",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yongshun Chen","professor","100507974","influence-mechanism-of-tumor-microenvironment-changes-on-neoadjuvant-therapy-for-esophageal-squamous-cell-carcinoma-100507974",false,"NCT05894369","Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma","Inclusion criteria：\n\nThe patient's age between 18 to 80 years old; Esophageal squamous cell carcinoma with definite pathological diagnosis and II-IVA clinical stage Preoperative neoadjuvant chemotherapy combined with immunotherapy The score of eastern cooperative oncology group is 0 \\~ 1 Exclusion criteria\n\nThe estimated survival time is less than 6 months; The first diagnosis had distant metastasis Suffering from malignant tumor or accompanying malignant disease in the past 5 years Pregnant or pregnant women. Vulnerable groups (those without informed ability, minors, vagrants, students and subordinates of researchers, employees of bidders)","ALL","18 Years","80 Years",{"count":51,"type":52},10,"ESTIMATED","1 Year","OBSERVATIONAL","To evaluate the predictive value and mechanism of inflammatory factors in peripheral blood on the prognosis of patients, and to explore the influencing factors of inflammation and tumor microenvironment on the efficacy of neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer. To explore the predictors of neoadjuvant therapy in patients with esophageal squamous cell carcinoma.",[57],"Esophageal Cancer",[59,60,61,62,63],"neoadjuvant therapy","immunotherapy","overall survival","efficacy","safety","2024-11-20",{"date":66,"type":67},"2024-11-25","ACTUAL",{"date":69,"type":67},"2023-05-04",{"date":71,"type":52},"2025-12-30",{"name":5,"class":6},1]